Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 13/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990678 | 0.84 | TGM2 (0.33) | EPHX2 | |
| SCHEMBL22368477 | 0.84 | TGM2 (0.33) | EPHX2 | |
| SCHEMBL19990782 | 0.84 | DUT (0.31) | — | |
| SCHEMBL22368498 | 0.73 | GLA (0.38) | CTSLEPHX2 | |
| SCHEMBL19990602 | 0.73 | GLA (0.38) | CTSLEPHX2 | |
| SCHEMBL3662286 | 0.67 | DPP8 (0.45) | EPHX2 | |
| SCHEMBL21362329 | 0.65 | DRD3 (0.53) | — | |
| SCHEMBL19872340 | 0.64 | TSHR (0.36) | — | |
| SCHEMBL15865519 | 0.64 | TSHR (0.36) | — | |
| SCHEMBL22368478 | 0.64 | BCHE (0.35) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | BACE1 11/4885BACE2 26/4885FKBP1A 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.